v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | NCT04595136 |
Full text link
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
|
First author
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
|
Contact
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Carlosrivg@gmail.com |
Registration date
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
2020-10-20 |
Recruitment status
Last imported at : May 9, 2023, midnight Source : ClinicalTrials.gov |
Unknown |
Study design
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
RCT |
Allocation
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Randomized |
Design
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Parallel |
Masking
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Blind label |
Center
Last imported at : March 15, 2023, 4 a.m. Source : ClinicalTrials.gov |
single-center |
Study aim
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Treatment |
Inclusion criteria
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
inclusion criteria: - provide written consent before being included in the essay. - positive cases of covid-19 (based on polymerase chain reaction or positive antigen test for sars-cov-2), - being diagnosed with mild to moderate sars-cov-2 disease (covid19) - symptomatic or asymptomatic patient, with good clinical appearance, sat o2 at rest > 94% with room air, and without desaturation with ambulation, and without tachypnea, - respiratory rate < 20. - suspected cases of covid-19, based on 3 criteria: - fever > 38 degrees celsius - o2 saturation ≤94 - abnormal laboratory indicators, any of them: - lymphopenia <1500 cells/m3 - c reactive protein >2 mg/l - ferritin >300g/l |
Exclusion criteria
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
- existing decompensated conditions such as diabetes mellitus, hypertension, coronary insufficiency, coronary artery disease, chronic obstructive pulmonary disease (or any chronic or severe lung disease), chronic kidney disease, cancer, immunosuppression, mood change - respiratory frequency > 20 / min, pulse > 120 bpm, systolic < 90 mmhg, diastolic < 60 mmhg - the patient seems toxic and distressed, or, o2 at rest <93% in ambient air, or desaturation when ambulating - being diagnosed with severe sars-cov-2 disease (covid19) - patients with low oxygen saturation levels, need for icu entry, need or likelihood of invasive mechanical ventilation - patients requiring bronchodilator treatment - patients with a known history of asthma and/or lung disease - patients with severe decompensated chronic obstructive pulmonary disease - patients who are unable to give consent or who are unable to follow up on the test group will be excluded |
Number of arms
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
2 |
Funding
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
United Medical Specialties |
Inclusion age min
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
18 |
Inclusion age max
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
100 |
Countries
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Colombia |
Type of patients
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Mild/moderate disease at enrollment |
Severity scale
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
2: Mild/moderate disease at enrollment |
Total sample size
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
60 |
primary outcome
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Change on viral load results from baseline after using COVID19-0001-USR via nebulization |
Notes
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
None |
Phase
Last imported at : Feb. 25, 2021, 7:58 p.m. Source : ClinicalTrials.gov |
Phase 1/Phase 2 |
Arms
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
[{"arm_notes": "", "treatment_id": 693, "treatment_name": "Ivermectin", "treatment_type": "Antiparasitics", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}] |